Eris Lifesciences declares interim dividend of ₹7.21 per share; approves FY26 results
Eris Lifesciences announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company declared an interim dividend of ₹7.21 per share for FY27. The record date for the dividend is May 29, 2026.
The declaration of an interim dividend directly benefits shareholders. The approval of financial results provides clarity on the company's performance.
The declaration of an interim dividend and approval of financial results with unmodified audit reports are positive indicators for the company.
Eris Lifesciences Limited announced the outcome of its Board of Directors meeting held on May 20, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The audit reports were submitted with unmodified opinions.
Additionally, the Board declared an interim dividend of ₹7.21 per equity share (721% on face value of Re. 1) for the Financial Year 2026-2027. The record date for this dividend has been fixed as Friday, May 29, 2026, with the payment scheduled on or before June 19, 2026.
The meeting commenced at 11:00 A.M. and concluded at 02:30 P.M.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.